Graft versus Host Disease (GvHD) Market Insights, Epidemiology & Forecast to 2027 - ResearchAndMarkets.com

DUBLIN--()--The "Graft versus Host Disease (GvHD) - Market Insights, Epidemiology and Market Forecast - 2027" drug pipelines has been added to ResearchAndMarkets.com's offering.

The 7Mm Market of Graft Versus Host Disease (GvHD) was USD 353.5 Million in 2016, and is Expected to Increase at a CAGR from 2016-2027

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Graft versus Host Disease (GvHD) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

The Graft versus Host Disease (GvHD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Companies Mentioned

  • AbbVie
  • Amgen
  • Bristol Myers Squibb/ Ono Pharmaceuticals, Co. Ltd
  • CSL Behring
  • Elsalys Biotech
  • Enlivex Therapeutics
  • Genzyme Corporation
  • Incyte Corportaion
  • Janssen Biotech, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Kadmon Corporation
  • Kamada
  • Kiadis Pharma
  • Mallinckrodt
  • Neovii Biotech
  • Novartis
  • Takeda Pharmaceutical Company Limited
  • Wyeth Pharmaceuticals Inc.

Key Topics Covered:

1. Report Introduction

2. GvHD Market Overview at a Glance

3. Disease Background and Overview: Graft versus Host Disease (GvHD)

4. Epidemiology and Patient Population

5. Treatment Algorithm

6. Unmet Needs

7. Marketed Drugs

8. Emerging Therapies

9. Total Market Size of GvHD in 7MM

10. Market Drivers

11. Market Barriers

12. Appendix

13. Report Methodology

14. Sources Used

15. Consulting Services

16. Disclaimer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/thgpbd/graft_versus_host?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Immunosuppressive Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Immunosuppressive Drugs